Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/7/17 → 07/31/26 |
Funding
- Eli Lilly and Company: $202,876.00
MonarchE: A Randomized Open-Label Phase 3 Study of Abemaciclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk Node Positive Early Stage Hormone Receptor Positive
- Baer, Lea (CoI)
- Cohen, Jules A (CoI)
- Stopeck, Alison (CoI)
Project: Research